Systematic review and meta-analysis: Patient and programme impact of fixed-dose combination antiretroviral therapy

Tropical Medicine and International Health

Volumn 19, Issue 5, 2014, Pages 501-513

  Ramjan, Rubeena ^a   Calmy, Alexandra ^b,c   Vitoria, Marco ^d   Mills, Edward J ^e   Hill, Andrew ^f   Cooke, Graham ^a   Ford, Nathan ^d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e UNIVERSITY OF OTTAWA   (Canada)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adherence; Antiretrovirals; Fixed dose combinations; Virological suppression

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DRUG COMBINATION;

ADOLESCENCE; DATA SET; DATABASE; DISEASE TREATMENT; LITERATURE REVIEW; META-ANALYSIS; RISK FACTOR;

ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DATA BASE; HEALTH PROGRAM; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LANGUAGE; MEDICAL INFORMATION; MEDICATION COMPLIANCE; META ANALYSIS; OUTCOME ASSESSMENT; PILL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SELF REPORT; SYSTEMATIC REVIEW; DRUG COMBINATION; HIV INFECTIONS; PATIENT COMPLIANCE; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG COMBINATIONS; HIV INFECTIONS; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84898053265     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12297     Document Type: Article

References (42)

1. Airoldi M, Zaccarelli M, Bisi L et al. (2010) One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Preference and Adherence 4, 115-125.
2. Anonymous (2003) Fixed-Dose Combinations for HIV/AIDS, Tuberculosis, and Malaria. Report of a Meeting Held 16-18 December 2003. World Health Organization, Geneva.
3. Anonymous (2011) The Treatment 2.0 Framework for Action: Catalysing the Next Phase of Treatment, Care and Support. World Health Organization, Geneva, Switzerland.
4. Bangsberg DR, Ragland K, Monk A & Deeks SG (2010) A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 24, 2835-2840.
5. Barnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J & Newell ML (2011) Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. The Lancet Infectious Diseases, 11, 942-951.
6. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N & Ferradini L (2006) Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 20, 1163-1169.
7. Clotet B, Carmena J, Pulido F, Luque I & Rodriguez-Alcantara F (2004) Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients. HIV Clinical Trials 5, 33-39.
8. Cocohoba JM, Murphy P, Pietrandoni G & Guglielmo BJ (2012) Improved antiretroviral refill adherence in HIV-focused community pharmacies. Journal of the American Pharmacists Association 52, e67-e73.
9. Eron JJ, Yetzer ES, Ruane PJ et al. (2000) Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS 14, 671-681.
10. Fischl MA, Burnside AE Jr, Farthing CE et al. (2003) Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial. Pharmacotherapy 23, 1432-1440.
11. Fleiss JL (1993) The statistical basis of meta-analysis. Statistical Methods in Medical Research 2, 121-145.
12. Ford N, Darder M, Spelman T, Maclean E, Mills E & Boulle A (2010) Early adherence as a predictor of long-term virological suppression: five-year follow up of an observational cohort. PLoS ONE 5, 1-4.
13. Hodder SL, Mounzer K, Dejesus E et al. (2010) Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care and STDs 24, 87-96.
14. Homar F, Lozano V, Martinez-Gomez J et al. (2012) Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs. Health Economics Review 2, 16.
15. Hull M, Milan D, Chan K et al. (2013) Effects of Fixed Dose Combination (FDC) NRTIs on Regimen Switching During First Year of Therapy: Analysis of the CANOC Cohort. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, 3-6 March 2013. Abstract 579.
16. Juday T, Grimm K, Zoe-Powers A, Willig J & Kim E (2011) A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States. AIDS Care 23, 1154-1162.
17. Juni P, Altman DG & Egger M (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323, 42-46.
18. Kalichman SC, Cherry C, Amaral CM et al. (2010) Adherence to antiretroviral therapy and HIV transmission risks: implications for test-and-treat approaches to HIV prevention. AIDS Patient Care and STDs 24, 271-277.
19. Keiser P, Armas L, Sanchez J & Moreno S (2007) Better adherence to both tenofovir/emtricitabine and to efavirenz in individuals taking tenofovir/emtricitabine fixed dose nucleoside combination tablet: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney 2007. Abstract CDB358.
20. Lamarca A, Clumeck N, Plettenberg A et al. (2006) Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study). Journal of Acquired Immune Deficiency Syndromes 41, 598-606.
21. Legorreta A, Yu A, Chernicoff H, Gilmore A, Jordan J & Rosenzweig JC (2005) Adherence to combined Lamivudine + Zidovudine versus individual components: a community-based retrospective medicaid claims analysis. AIDS Care 17, 938-948.
22. Llibre JM, Arribas JR, Domingo P et al. (2011) Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. AIDS 25, 1683-1690.
23. Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG & Moyle GJ (2008) Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Medicine 9, 667-672.
24. Manfredini V, Vigano A, Murri R et al. (2011) One-pill once a day haart: Simplification strategy maintaining adherence, efficacy and improving physical and psychological outcomes in a cohort of HIV-infected adolescents and youths. Italian Conference on AIDS and Retroviruses, Italy 2011
25. Marcum ZA, Sevick MA & Handler SM (2013) Medication nonadherence: a diagnosable and treatable medical condition. JAMA, 309, 2105-2106.
26. Matambo T, Hildebrand K, Mwongera C et al. (2012) Targeted adherence strategies for provision of cross border antiretroviral therapy (ART) to migrant farm workers in Musina, South Africa.: 19th International AIDS Conference, Washington 22-27 July 2012. Abstract TUPE752.
27. Moher D, Liberati A, Tetzlaff J & Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 6, e1000097.
28. Morris MB, Chapula BT, Chi BH et al. (2009) Use of task-shifting to rapidly scale-up HIV treatment services: experiences from Lusaka, Zambia. BMC Health Services Research 9, 5.
29. Mosen DM, Horberg M, Roblin D et al. (2010) Effect of once-daily FDC treatment era on initiation of cART. HIV/AIDS 2, 19-26.
30. Nachega JB, Parienti JJ, Uthman OA et al. (2014) Lower Pill Burden and Once-daily Dosing Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials. Clinical Infectious Diseases. [Epub ahead of print].
31. Parienti JJ, Bangsberg D, Verdon R, Gardner EM (2009) Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clinical Infectious Diseases 48, 484-488.
32. Pasquet A, Messou E, Gabillard D et al. (2010) Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Cote d'Ivoire. PloS ONE 5, e13414.
33. Rosso R, di Biagio A, Maggiolo F et al. (2012) Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen. AIDS Care 24, 54-58.
34. Rutland E & Mani R (2009) Patient treatment satisfaction after simplification to a fixed-dose combination of efavirenz/emtricitabine/tenofovir. HIV Medicine 10(Suppl. 1), 24.
35. Sanchez CA, Medrano J, Labarga P, Vispo E, Calvino A & Martin-Carbonero L. (2006) Efficacy and safety of TDF+FTC+EFV in naive patients initiating HAART; an observational study comparing Atripla Vs Truvada/Sustiva exposure. 16th International Symposium on HIV and Emerging Infectious Diseases France 2006.
36. Sosa N, Hill-Zabala C, Dejesus E et al. (2005) Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). Journal of Acquired Immune Deficiency Syndromes 40, 422-427.
37. Sterrantino GM, Trotta M, Ambu S, Borchi B & Leoncini F (2006) Evaluation of safety, efficacy and adherence of atripla treatment in 74 patient switching from truva and sestina therapy. Italian Conference on AIDS and Retroviruses, Italy 2006.
38. Sterrantino G, Santoro L, Bartolozzi D, Trotta M & Zaccarelli M (2012) Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era. Patient Preference and Adherence 6, 427-433.
39. Walensky RP, Paltiel AD & Schackman BR (2013) Cost-effectiveness of generic antiretroviral therapy. Annals of Internal Medicine 158, 776-777.
40. Watson M, Hill-Zabala C, Sosa N, Dejesus E & Florance A (2004) Patient satisfaction with abacavir (ABC)-lamivudine (3TC) fixed dose combination (FDC) tablet once daily (QD) compared with ABC and 3TC twice daily (BID) in HIV-1 infected patients (ESS30008). Seventh International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2004.
41. Willig JH, Abroms S, Westfall AO et al. (2008) Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 22, 1951-1960.
42. Wood E, Hogg RS, Yip B et al. (2003) Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4 + cell count is 0.200 to 0.350 x 10(9) cells/L. Annals of Internal Medicine 139, 810-816.